Welcome to our dedicated page for MDB Capital Holdings news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings stock.
MDB Capital Holdings, LLC (NASDAQ: MDBH) is an innovative investment holding company that specializes in supporting early-stage technology companies through public offerings. Founded in 1997 and headquartered in Addison, Texas, MDB Capital Holdings operates through two primary segments: a broker-dealer & intellectual property service, and a technology development segment. The broker-dealer & intellectual property service, which is a significant revenue driver, focuses on private and public securities offerings and provides in-depth patent research for investment banking due diligence.
MDB Capital Holdings is committed to backing visionary technologies, inventors, and entrepreneurs. This commitment has led to the successful launch of 16 companies under its unique public venture capital model. This model aims to finance pre-revenue, early-stage companies primarily listed on NASDAQ. In September 2023, MDB Capital Holdings raised nearly $20 million and began trading on NASDAQ under the ticker symbol ‘MDBH’.
The company operates through its wholly-owned subsidiaries, Public Ventures, LLC and Patentvest, Inc., and has a majority ownership stake in Invizyne Technologies, Inc., a leader in enzyme-based biomanufacturing technology. Public Ventures, an SEC registered and FINRA member broker-dealer, is expanding its business scope to include self-clearing capabilities to enhance its investment banking services.
MDB Capital Holdings' recent achievements include a successful IPO, raising significant capital to further its mission, and advancing its self-clearing broker-dealer capabilities. The company also boasts significant expertise and success in transforming ‘Big Ideas’ into valuable public companies, demonstrated through their strategic and technological advancements.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
MDB Capital Holdings (NASDAQ: MDBH) has scheduled a Zoom webinar for Thursday, November 21, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 results. CEO Christopher Marlett will lead the presentation, accompanied by management team members, to review recent developments, ongoing initiatives, and anticipated milestones. The company will release detailed financial results before the call. Investors can pre-register for the webinar through a provided link or access it via MDB's investor relations website.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.
Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.
Invizyne Technologies has announced the pricing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share, raising $15 million in gross proceeds. Trading will begin on Nasdaq under ticker 'IZTC' on November 12, 2024. The company granted a 45-day over-allotment option for 281,250 additional shares and will issue 184,375 warrants in a concurrent private placement. Proceeds will fund production expansion, business development, sales and marketing, loan repayment, and working capital. The offering is expected to close on November 13, 2024, with MDB Capital acting as underwriter.
MDB Capital Holdings, (NASDAQ: MDBH) has announced its sponsorship of TCA Venture Group, one of the largest angel investor networks in Southern California. The partnership, which began in August 2024, aims to provide TCA's angel investors with insights into public venture investing and potential future collaboration opportunities.
As part of this initiative, MDB will share deep tech insights and co-host events with TCA. The first joint event is scheduled for October 21, 2024, featuring Lou Basenese, MDB Capital President & Chief Market Strategist, and Dave Berkus, TCA Chairman Emeritus, discussing 'Traditional Venture vs Public Venture'. This virtual event is open to all individual and angel investors.
The sponsorship is expected to support TCA through events across its network and assist portfolio companies with their exit plans. Both organizations express excitement about the collaboration and its potential benefits for entrepreneurs and investors in the innovation industry.
MDB Capital Holdings has announced the record date and expected timing for the IPO of its subsidiary, Invizyne Technologies. The record date for allocation preferences is set for July 22, 2024, with the IPO expected to close and start trading on NASDAQ on or before August 15, 2024. Invizyne, specializing in cell-free, enzyme-based biomanufacturing systems, aims to raise $17.2 million by offering 4,300,000 shares at $4.00 per share. MDB Class A shareholders will have allocation preferences in this IPO, with additional shares potentially available on a pro-rata basis. Interested investors must contact MDB Capital by August 5, 2024, to indicate the number of shares sought.
PatentVest, a leading IP intelligence strategy and law firm, recently published a whitepaper exploring innovations in MASH (Metabolic-Associated Steatohepatitis) diagnostics. The document offers strategic insights into MASH biomarkers and Point of Care (PoC) kits for detecting and monitoring this condition. Key drivers include the recent approval of the MASH drug, Rezdiffra, and an increase in patenting activities. Emerging patent opportunities are identified in non-invasive diagnostic techniques, multi-biomarker tools, and personalized medicine approaches. This whitepaper aims to guide stakeholders in navigating the competitive landscape by leveraging innovation and IP protection. The full report is available on the PatentVest website.
FAQ
What is the current stock price of MDB Capital Holdings (MDBH)?
What is the market cap of MDB Capital Holdings (MDBH)?
What does MDB Capital Holdings, LLC do?
What is the core business of MDB Capital Holdings?
What are the main segments of MDB Capital Holdings?
What recent achievements has MDB Capital Holdings accomplished?
What is the ticker symbol for MDB Capital Holdings?
Who are the subsidiaries of MDB Capital Holdings?
What is Invizyne Technologies, Inc.?
How does MDB Capital Holdings support technology companies?
What is the mission of MDB Capital Holdings?
